Core Insights - Tianjing Biological (IMAB) opened with a 2.57% increase on August 18, reaching $4.995 per share, with a total market capitalization of $574 million [1] - The company reported total revenue of 27.644 million RMB for the year ending December 31, 2023, representing a year-on-year growth of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, an increase of 41.54% year-on-year [1] Company Overview - Tianjing Biological is an offshore holding company registered abroad, operating through its domestic subsidiary Tianjing Biological, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2] - The company aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, addressing unmet clinical needs and improving the quality of life for patients worldwide [2] - The mission of the company is to become a leading biopharmaceutical company rooted in China and oriented towards global markets [2]

8月15日，天境生物(IMAB)盘中上涨11.01%，截至21:44，报5.728美元/股，成交579.98万美元，总市值 6.59亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 大事提醒： 本文源自：金融界 作者：行情君 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 ...

Core Viewpoint - Tianjing Bio (IMAB) is focused on developing innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases, aiming to fill clinical treatment gaps and improve patient survival globally [1]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 interim report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company registered abroad, operating through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1]. - The company's mission is to create groundbreaking innovative biopharmaceuticals that address unmet clinical needs and significantly enhance the quality of life for patients worldwide [1].

本文源自：金融界 大事提醒： 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 8月14日，天境生物(IMAB)盘中上涨10.61%，截至21:37，报4.69美元/股，成交223.05万美元，总市值 5.39亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 作者：行情君 ...

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year improvement of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year increase of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1] Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1] - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year improvement of 41.54% [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1] - The company's mission is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [1] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [1]

Core Viewpoint - I-Mab has successfully completed enrollment in the Phase 1b dose expansion cohorts for givastomig, a bispecific antibody targeting Claudin 18.2, ahead of expectations, indicating strong interest and unmet needs in gastric cancer therapy [1][3]. Group 1: Study Details - The Phase 1b study (NCT04900818) is focused on evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig in combination with nivolumab and mFOLFOX6 for CLDN18.2-positive gastric cancers [2]. - A total of 40 patients were enrolled in the dose expansion cohorts, with two doses being tested: 8 mg/kg and 12 mg/kg [2]. - The primary endpoint of the study is safety, and it exclusively enrolled patients in the U.S. [2]. Group 2: Clinical Data and Results - Data presented at the ESMO GI 2025 indicated an 83% objective response rate (ORR) for givastomig in combination with immunochemotherapy at the selected doses [3][8]. - The response onset was reported to be rapid, durable, and deepened over time, with favorable overall safety [3]. Group 3: Product Overview - Givastomig is a bispecific antibody designed to target Claudin 18.2-positive tumor cells and conditionally activate T cells through the 4-1BB signaling pathway [4][7]. - The drug is being developed for first-line metastatic gastric cancers, with potential applications in other solid tumors [4][7]. Group 4: Development Partnership - Givastomig is being developed through a global partnership with ABL Bio, where I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio [6]. Group 5: Future Expectations - The company expects to release topline results from the Phase 1b study in Q1 2026, following the positive data from the dose escalation phase [8].

Group 1 - The core viewpoint of the news is that Tianjing Biopharma (IMAB) has shown significant financial growth, with a notable increase in revenue and a decrease in net profit loss, indicating potential for future investment opportunities [1][2]. - As of August 8, 2023, Tianjing Biopharma's stock opened at $3.601 per share, reflecting a 2.6% increase, with a total market capitalization of $414 million [1]. - The company's total revenue for the year ending December 31, 2023, was reported at 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. Group 2 - Tianjing Biopharma is focused on developing innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases, aiming to create "first-in-class" and "best-in-class" therapies [2]. - The company is set to disclose its fiscal year 2024 mid-term report on August 28, 2023, which is anticipated to provide further insights into its financial performance [2]. - The mission of Tianjing Biopharma is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant stock performance and financial growth, indicating potential investment opportunities in the innovative biopharmaceutical sector focused on oncology and autoimmune diseases [1]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential in the global market [1]. - The company's mission is to develop groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients worldwide [1].